Dermatology News and Research

Latest Dermatology News and Research

New guidelines from American Academy of Dermatology for treatment of psoriasis with ultraviolet light therapy

Based on an extensive review of the highest quality scientific literature on psoriasis and the opinion of recognized psoriasis experts, the American Academy of Dermatology (Academy) has released new guidelines of care for the management and treatment of psoriasis with ultraviolet (UV) light therapy, also known as phototherapy. Recommendations for the use of the most common forms of UV light therapy, as stand-alone treatments or in conjunction with other therapies, were outlined, including patient considerations.

23 Oct 2009

Faster insulin absorption for varying insulin doses and PH20 concentrations demonstrated

Halozyme Therapeutics, Inc. today announced dose response study results that demonstrated faster insulin absorption and increased peak insulin concentrations after co-administration of its recombinant hyaluronidase enzyme (rHuPH20 or PH20) with regular human insulin and with insulin lispro. The enhanced absorption effects were observed at clinically relevant insulin doses across a broad range of PH20 concentrations.

22 Oct 2009

New corporate communication policy implemented at Senetek

Senetek PLC, a Life Sciences company engaged in the research, development and commercialization of technologies that target the science of healthy aging, today announced that the Senetek Board of Directors has implemented a new Corporate Communication policy to insure that the highest standards of corporate governance are met and that full compliance with all public company regulations is in place.

22 Oct 2009

Halozyme Therapeutics commences patient dosing in Phase 3 Enhanze trial with Herceptin

Halozyme Therapeutics, Inc. and Roche today announced dosing of the first patient in a Phase 3 registration trial using Enhanze™ technology (rHuPH20, recombinant human hyaluronidase) in a subcutaneous formulation with Roche’s anticancer biologic, Herceptin (trastuzumab).

22 Oct 2009

Study compares effects of clin-BPO 2.5% and clin-BPO 5% on epidermal functions

Dermatologists agree that topical fixed-combination products containing clindamycin (clin) and benzoyl peroxide (BPO) are effective in the treatment of acne. However, products containing BPO concentrations at 5% or higher may limit use due to associated dryness and irritation in some patients.

22 Oct 2009

DUSA Pharmaceuticals finds place in Deloitte's Technology Fast 500 list for second consecutive year

DUSA Pharmaceuticals, Inc.(R)( )(Nasdaq: DUSA), a specialty pharmaceutical company focused on dermatology, announced today that it has been named to Deloitte's Technology Fast 500 list. For the second consecutive year, Deloitte recognized DUSA as one of the Top 500 fastest growing technology, media, telecommunications and life sciences companies in North America in terms of percentage revenue growth over a five year period.

21 Oct 2009

New dual-port ophthalmic green laser photocoagulator introduced by IRIDEX

IRIDEX Corporation today announced the introduction of the IQ 532(TM) dual-port ophthalmic green laser photocoagulator which will be featured at the 2009 American Academy of Ophthalmology meeting in San Francisco.

21 Oct 2009

IRIDEX announces launch of a Modular Multi-Wavelength laser photocoagulator solution

IRIDEX Corporation today announced the introduction of a Modular Multi-Wavelength laser photocoagulator solution, which will be featured at the 2009 American Academy of Ophthalmology meeting in San Francisco.

21 Oct 2009

Non-invasive tool to increase facial volume and reverse some of the visible signs of aging

Faces don't lie when it comes to showing signs of aging. Yet gravity alone is not the sole determinant of the aging face. Studies have demonstrated that volume loss of soft tissue and bone is at least equally important to facial aging. The loss of volume in the face over time can cause deep lines, sunken areas around the eyes, temples, nose and jowls.

20 Oct 2009

Encorium Group raises $1.6 million through private placement

Encorium Group, Inc., a full-service multinational contract research organization (CRO) that provides design, development, and management capabilities for clinical trials and patient registries to many of the world's leading pharmaceutical companies, today announced that it has completed a private placement of 3,937,500 shares of its common stock with a private investor for an aggregate purchase price of $1,575,000, or $.40 per share.

19 Oct 2009

HealthScape Consumer to analyze patient and consumer data

Healthy Advice Networks, the nation's leading provider of physician office-based patient-education programs, announces a groundbreaking measurement program to track consumer purchase behavior, not just purchase intent, for OTC and consumer health brands.

19 Oct 2009

Sangretech Biomedical signs amended license agreement with Bostwick Laboratories

Sangretech Biomedical LLC, a developer of dendritic cell therapies for cancer and infectious diseases, today announced it has executed an amended and restated license agreement with Bostwick Laboratories, Inc. providing Bostwick Scientific, the research division of Bostwick Laboratories, with exclusive rights to Sangretech’s dendritic cell technology in certain territories.

15 Oct 2009

National Biological to market Quantel's 308 Excimer System in the U.S.

Quantel SA (Euronext: QUA), a leading manufacturer of solid state lasers, announced today that it has entered into a Distribution Agreement with National Biological, a leading researcher and developer of light-based systems for medical and cosmetic treatments, for Quantel's 308 Excimer System for monochromatic UVB treatment of psoriasis and vitiligo in the United States.

15 Oct 2009

More than half RCTs do not report vital information about study populations race, says study

A new study recently published online by the American Heart Journal shows that more than half of all randomized clinical trials, or RCTs, for cardiovascular disease are not reporting vital information about the study populations race or ethnicity. NYU School of Medicine researchers found that out of the 156 cardiovascular disease RCTs analyzed, only 35% of trials reported any information on race or ethnicity between 1970 and 2006. From 2000 to 2006, 46% of trials included that information.

15 Oct 2009

APN and Cardinal Health sign agreement to help improve practice operations

Aesyntix Physician Network (APN), a leading national group purchasing organization (GPO) for dermatologists and plastic surgeons, today announced it has signed an agreement with Cardinal Health to provide APN members with products and services designed specifically for dermatologists and plastic surgeons.

15 Oct 2009

Provectus Pharmaceuticals commences compassionate use program of PV-10 for cancer

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has expanded its compassionate use program for PV-10, making the agent, which is being developed as a therapeutic agent for a broad spectrum of cancers, available for select cancer patients in the United States. The program is already in progress in Australia, where it was initiated in June 2009.

14 Oct 2009

NanoBio to receive a $4.1M subcontract for developing nanoemulsion-based mucosal vaccine adjuvants

NanoBio Corporation today announced an award from the National Institute of Allergy and Infectious Diseases, a Division of The National Institute of Health, to fund vaccine research associated with “Innate Immune Receptors and Adjuvant Discovery.” NanoBio is the principal subcontractor for the $9.3 million contract awarded to the University of Michigan.

14 Oct 2009

Systagenix Wound Management forms new global Medical Advisory Board

Systagenix Wound Management has announced the formation of a new global Medical Advisory Board, consisting of a group of multi-disciplinary and highly respected wound care clinicians and practitioners from North America and Europe, which will be led by Systagenix's newly appointed Medical Director, Dr Robert Snyder.

13 Oct 2009

Provectus Pharmaceuticals completes initial treatment in Phase 2 trial of PH-10 for plaque psoriasis

Provectus Pharmaceuticals, Inc., a development stage oncology and dermatology biopharmaceutical company, has completed patient accrual and initial treatment in its Phase 2 trial of PH-10 for the treatment of plaque psoriasis. This milestone marks the third Phase 2 clinical trial for which Provectus has completed patient accrual since May 2009.

13 Oct 2009

Psoriasis patients taking immunosuppressive drugs at increased risk of H1N1 flu viruses

People with psoriasis and/or psoriatic arthritis who are taking biologic or non-biologic immunosuppressive medications should receive the inactived forms of both seasonal influenza and H1N1 (swine flu) vaccines as soon as possible, according to a recommendation from the National Psoriasis Foundation.

13 Oct 2009

Dermatology News and Research

Latest Dermatology News and Research

New guidelines from American Academy of Dermatology for treatment of psoriasis with ultraviolet light therapy

Faster insulin absorption for varying insulin doses and PH20 concentrations demonstrated

New corporate communication policy implemented at Senetek

Halozyme Therapeutics commences patient dosing in Phase 3 Enhanze trial with Herceptin

Study compares effects of clin-BPO 2.5% and clin-BPO 5% on epidermal functions

DUSA Pharmaceuticals finds place in Deloitte's Technology Fast 500 list for second consecutive year

New dual-port ophthalmic green laser photocoagulator introduced by IRIDEX

IRIDEX announces launch of a Modular Multi-Wavelength laser photocoagulator solution

Non-invasive tool to increase facial volume and reverse some of the visible signs of aging

Encorium Group raises $1.6 million through private placement

HealthScape Consumer to analyze patient and consumer data

Sangretech Biomedical signs amended license agreement with Bostwick Laboratories

National Biological to market Quantel's 308 Excimer System in the U.S.

More than half RCTs do not report vital information about study populations race, says study

APN and Cardinal Health sign agreement to help improve practice operations

Provectus Pharmaceuticals commences compassionate use program of PV-10 for cancer

NanoBio to receive a $4.1M subcontract for developing nanoemulsion-based mucosal vaccine adjuvants

Systagenix Wound Management forms new global Medical Advisory Board

Provectus Pharmaceuticals completes initial treatment in Phase 2 trial of PH-10 for plaque psoriasis

Psoriasis patients taking immunosuppressive drugs at increased risk of H1N1 flu viruses

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Dermatology News and Research

Latest Dermatology News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in